**Name of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 17409**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Study***

**Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection**

Lin ZX *et al*.LMR predicts survival in HCC

Ze-Xiao Lin, Dan-Yun Ruan, Yang Li, Dong-Hao Wu, Xiao-Kun Ma, Jie Chen, Zhan-Hong Chen, Xing Li, Tian-Tian Wang, Qu Lin, Jing-Yun Wen, Xiang-Yuan Wu

**Ze-Xiao Lin, Dan-Yun Ruan, Dong-Hao Wu, Xiao-Kun Ma, Jie Chen, Zhan-Hong Chen, Xing Li, Tian-Tian Wang, Qu Lin, Jing-Yun Wen, Xiang-Yuan Wu**, Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong Province, China

**Yang Li,** Department of Liver Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong Province, China

**Author contributions:** Lin ZX, Ruan DY and Li Y contribute to this work equally and should be regarded as co-first authors; Lin ZX, Ruan DY and Li Y conceived and designed the study; Wu DH, Ma XK, Chen J, Chen ZH, Li X, Wang TT, Lin Q and Wen JY performed the study; Lin ZX, Ruan DY, Li Y analyzed the data; Lin ZX drafted and revised the manuscript; all authors have read and approved the final manuscript.

**Supported by** National Natural Science Foundation of China, No. 81372374; grants from the Combination Project of Production, Education and Research from Guangdong Province and Ministry of Education, No. 2012B091100460; and the Natural Science Foundation of Guangdong, No. 2014A030313146.

**Institutional review board statement:** This study protocol was approved by the Clinical Ethics Review Board of The Third Affiliated Hospital of Sun Yat-sen University.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** None of the authors declared a potential conflict of interest related to this manuscript. None of the authors have received a fee for serving as a speaker for any organization, and none have received research funding from any organization. The authors are not employees of any organization and do not own stocks and/or shares in any organization. The authors do not own patents.

**Data sharing statement:** Technical appendix, statistical code, and dataset are available from the corresponding author at wuxiangy@mail.sysu.edu.cn. Participants provided informed consent for data sharing. No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Correspondence to:** **Xiang-Yuan Wu, MD, Professor, Chief,** Department of Medical Oncology, The Third Affiliated Hospital of Sun Yat-sen University, No. 600 Tianhe Road, Guangzhou 510630, Guangdong Province, China. wuxiangy@mail.sysu.edu.cn

**Telephone:** +86-20-85252217

**Fax:** +86-20-85252092

**Received:** March 5, 2015

**Peer-review started:** March 6, 2015

**First decision:** April 24, 2015

**Revised:** May 11, 2015

**Accepted:** August 29, 2015

**Article in press:**

**Published online:**

**Abstract**

**AIM:** To investigate the prognostic value of preoperative lymphocyte-to-monocyte ratio (LMR) in patients with hepatocellular carcinoma (HCC) undergoing curative hepatectomy.

**METHODS:** Clinicopathological data from 210 hepatitis B virus (HBV)-associated HCC patients who were treated with radical hepatic resection between 2003 and 2010 was retrospectively analyzed. None of the patients received any preoperative anticancer therapy or intraoperative radiofrequency ablation. The diagnosis was confirmed by pathological examination after surgery. Absolute peripheral blood lymphocyte and monocyte counts were derived from serum complete blood cell count before surgery, and LMR was calculated by dividing lymphocyte count by monocyte count. The best cutoff was determined by receiver operating characteristics (ROC) curve analysis. Correlations between LMR levels and clinicopathological features were assessed using the chi-square test. Survival outcomes were estimated using the Kaplan-Meier method and compared by the log-rank test. Univariate and multivariate analyses were performed to evaluate the prognostic impact of LMR and other clinicopathological factors on overall survival (OS) and recurrence-free survival (RFS), using the Cox proportional hazards model.

**RESULTS:** The optimal cutoff value of LMR for survival analysis was 3.23, which resulted in the most appropriate sensitivity of 55.3% and specificity of 74.7%, with the area under the curve (AUC) of 0.66 (95%CI: 0.593-0.725). All patients were dichotomized into either a low (≤ 3.23) LMR group (*n =* 66) or a high (> 3.23) LMR group (*n =* 144). A low preoperative LMR level was significantly correlated with the presence of cirrhosis, elevated levels of total bilirubin and larger tumor size. Patients with a low LMR level had significantly reduced 5-year OS (61.9% *vs* 83.2%, *P* < 0.001) and RFS (27.8% *vs* 47.6%, *P* = 0.009) compared to those with a high LMR level. Multivariate analyses indicated that a lower LMR level was a significantly independent predictor for inferior OS (*P* = 0.003) and RFS (*P* = 0.006). Subgroup analysis indicated that survival outcome was significantly more favorable in cirrhotic patients with LMR > 3.23. However, there were no differences between low and high LMR groups for OS and RFS in non-cirrhotic patients.

**CONCLUSION:** Preoperative LMR was demonstrated for the first time to serve as an independent prognostic factor in HBV-associated HCC patients after curative resection. Prospective studies with larger cohorts for validation are warranted.

**Key words:** Hepatocellular carcinoma; Liver resection; Lymphocyte-to-monocyte ratio; Prognosis; Prognostic factor

**© The Author(s) 2015.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Inflammatory microenvironment plays an important role in the progression of hepatocellular carcinoma (HCC). Peripheral blood lymphocyte-to-monocyte ratio (LMR), a novel inflammatory biomarker that combines estimates of host immune homeostasis and tumor microenvironment, has been found to serve as a predictor of clinical outcomes in various malignancies. Prior to this study, here have been no reports regarding the prognostic value of LMR in HCC patients. For the first time in literature, our study identified the optimal cutoff value of LMR for survival analysis and concluded that preoperative LMR could serve as an independent prognostic factor in hepatitis B virus-associated HCC patients after curative resection.

Lin ZX, Ruan DY, Li Y, Wu DH, Ma XK, Chen J, Chen ZH, Li X, Wang TT, Lin Q, Wen JY, Wu XY. Lymphocyte-to-monocyte ratio predicts survival of patients with hepatocellular carcinoma after curative resection. *World J Gastroenterol* 2015; In press

**INTRODUCTION**

Hepatocellular carcinoma (HCC) is one of the leading types of malignant tumors worldwide, which primarily develops in the setting of chronic liver inflammation[1]. In China, nearly 90% of HCC patients have underlying hepatitis B virus (HBV) infection. Hepatic resection has been established as a curative treatment for patients who have localized lesions arising in non-cirrhotic livers, or in cirrhotic livers with well-preserved hepatic function[2]. However, the long-term survival after resection remains dismal due to a high frequency of tumor recurrence[3-5]. Clinicopathological factors, such as microvascular invasion, multifocal disease, tumor size and degree of histologic differentiation, have been used to predict survival in patients with HCC after curative resection[3-6]. However, these clinical tumor parameters can only partially explain the prognostic heterogeneity of HCC.

Cumulative evidence has demonstrated that crosstalk between tumor cells and their surrounding inflammatory microenvironment plays a critical role in the initiation and progression of HCC. Inflammatory infiltrates in the tumor microenvironment can largely influence the biological behavior of HCC[7-12]. Tumor-associated macrophages (TAMs), which comprise a major proportion of leukocytes that infiltrate into the stroma, have been found to promote HCC proliferation, angiogenesis and metastasis[7,11-14]. Immunohistochemical studies have validated the association between high TAMs density and unfavorable prognosis in HCC patients after curative resection[15,16]. Peripheral blood monocytes, which are precursors of TAMs[7], have also been reported to be a prognostic factor for HCC[17,18]. Tumor-infiltrating lymphocytes (TILs) are another representative component of the immune microenvironment. Specific TIL subtypes are involved in the clinical course of HCC, and TIL phenotypes are informative regarding prognosis[8-10,13].

Recently, the peripheral blood lymphocyte-to-monocyte ratio (LMR), as a simple surrogate biomarker of TILs and TAMs, has been reported to be a predictor of clinical outcomes in various malignancies[19-25]. LMR also acts as a representative biomarker by combining estimates of host immune homeostasis (*i.e*., absolute lymphocyte count) and tumor microenvironment (*i.e*., absolute monocyte count)[19,20]. To date, there have been no reports regarding the prognostic value of LMR in HCC patients. We therefore conducted this study to investigate the impact of preoperative peripheral blood LMR on long-term outcomes after curative hepatic resection for HCC.

**MATERIALS AND METHODS**

***Patient enrollment and clinicopathological variables***

HBV-associated HCC who underwent curative hepatectomy at the Third Affiliated Hospital of Sun Yat-sen University were eligible for this retrospective study. All the patients had chronic HBV infection and were negative for hepatitis C virus antibody. Preoperative diagnosis of HCC was based on typical dynamic images evaluated by contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) according to the Asian Pacific Association for the Study of the Liver (APASL) guideline[26]. Pathological examination confirmed the diagnosis after surgical resection. Curative resection was defined as the complete resection of all tumor nodules with clear microscopic margins and no residual tumors as indicated by computed tomography (CT) scan at one month after surgery. Neither preoperative anticancer therapy nor intraoperative radiofrequency ablation was performed on the patients. Antiviral therapy with oral nucleos(t)ide analogues was recommended for all the patients after liver resection.

For each patients in the group, demographic information, complete blood cell count, liver function parameters, serum alpha-fetoprotein (AFP) level, Barcelona Clinic Liver Cancer (BCLC) stage, and other tumor-related parameters were recorded. Tumor-related variables, such as maximal tumor diameter, number of tumor nodules, portal vein thrombus and histological differentiation, were obtained from pathology reports. The absolute peripheral blood lymphocyte and monocyte counts were derived from the complete blood cell count before surgery, with LMR calculated by dividing lymphocyte count by monocyte count. None of the patients exhibited clinical manifestations of acute inflammation before treatment or of coexistent hematologic disorders. The study protocol was approved by the Clinical Ethics Review Board of the Third Affiliated Hospital of Sun Yat-sen University. Informed consent was obtained according to the Declaration of Helsinki.

***Follow-up***

All patients were regularly followed up for recurrence at outpatient clinics. None of the patients died within 30 days after surgery. Serum AFP test and abdominal CT scan were performed every 3 months during the first two postoperative years and every 6 months thereafter. If clinical recurrence was suspected, CT was performed immediately. Additional diagnostic investigation such as MRI or hepatic arterial angiography was performed in patients with suspicious lesions demonstrated by CT image. Patients with confirmed recurrence received further treatment, such as second hepatectomy, chemoembolization, radiofrequency ablation or percutaneous ethanol injection. Treatment modality after relapse varied among individuals.

***Statistical analysis***

Receiver operating curve (ROC) analysis was performed to determine the optimal cutoff values for preoperative absolute lymphocyte count (ALC), absolute monocyte count (AMC) and LMR as prognostic factors. The score closest to the point with both maximum sensitivity and specificity was chosen as the best cutoff value. Correlations between LMR levels and clinicopathological features were assessed using the chi-square test. Survival outcomes were estimated using the Kaplan-Meier method and compared by the log-rank test. The primary endpoint of the present study was overall survival (OS), which was calculated from the time of surgery to the date of death from any cause, or to the date of the last follow-up. The secondary end point was recurrence-free survival (RFS), which was defined as the duration from the date of surgery to the date of HCC recurrence, or to the date of the last follow-up. The prognostic values of ALC, AMC, LMR and other clinicopathological factors were analyzed using the Cox proportional hazards model. Significant variables identified in univariate analysis were included in the multivariate model. A *P*-value < 0.05 was regarded as statistically significant. All statistical analyses were performed using SPSS software (version 17.0, SPSS Inc, Chicago, USA) and MedCalc statistical software (version 11.4.2.0, Broekstraat 52 Mariakerke, Belgium).

**RESULTS**

***Patients’ characteristics and outcomes***

The patients had chronic HBV infection and 161 (76.7%) patients had a histological diagnosis of cirrhosis. The median duration of follow-up was 34.8 mo (range: 1.7-106.6 mo). By the last follow-up, 110 patients (52.4%) developed tumor recurrence, 47 patients (22.9%) died from causes secondary to HCC progression, and one patients died from cerebrovascular disease. The 1-, 3-, and 5-year OS rates for all the patients in this study were 95.7%, 80.9% and 75.6%, respectively, and the 1-, 3-, and 5-year RFS rates were 69.9%, 51.7% and 42.3%, respectively.

***The optimal cutoff values of LMR, ALC and AMC for survival analyses***

The best cutoff points of LMR, ALC and AMC for survival outcomes were determined by ROC curve analyses, which indicated that the optimal LMR cutoff value for both OS and RFS was 3.23. The LMR cutoff point of 3.23 for OS was selected as the uniform point in survival analyses (Figure 1). The area under the curve (AUC) was recorded as 0.66 (95%CI: 0.593-0.725). Using the LMR value of 3.23 resulted in the most appropriate measures of sensitivity and specificity, which were 55.3% and 74.7%, respectively. Similarly, the most discriminative cutoff values of ALC and AMC were determined to be 1.66 × 109/L (AUC: 0.58, 95%CI: 0.511-0.648) and 0.29 × 109/L (AUC: 0.61, 95%CI: 0.542-0.678), respectively.

***Correlations between preoperative LMR and clinicopathological factors***

Based on the cutoff value, all patients were dichotomized into either a low value group or a high value group. The relationship between preoperative peripheral LMR levels and clinical pathologic characteristics was summarized in Table 1. Sixty-six patients had an LMR ≤ 3.23 and one hundred and forty-four patients had an LMR > 3.23. A low LMR level was significantly correlated with ALC ≤ 1.66 (*P* < 0.001) and AMC > 0.29 (*P* < 0.001). Patients with LMR ≤ 3.23 were also prone to have liver cirrhosis (*P* =0.003), elevated levels of total bilirubin (*P* = 0.002) and larger tumor size (*P* = 0.030).

***Univariate and multivariate analyses***

To identify the optimal peripheral blood immunological biomarker for patient prognosis, the impacts of ALC, AMC and LMR on survival outcomes were investigated. In univariate analysis for primary endpoint of OS, ALC and AMC were shown to be significant prognostic factors, with a *P* value = 0.035 for ALC [hazard ratio (HR) = 0.511, 95%CI: 0.274 – 0.953] and a *P* value = 0.026 for AMC (HR = 2.644, 95%CI: 1.123–6.223). The association between LMR and OS was also proven to be statistically significant, with a *P-*value < 0.001 (HR = 0.352, 95%CI: 0.199–0.623), indicating that LMR might provide the strongest prognostic information among these three biomarkers (Table 2). With respect to RFS, significant differences were also observed between low and high LMR groups (*P =* 0.009, HR = 0.601, 95%CI: 0.410–0.883) (Table 3). Other significant predictors of poorer OS and RFS included a low level of serum albumin, large tumor size, the presence of portal vein thrombus, poor histological differentiation, and an advanced BCLC stage. Moreover, liver cirrhosis, an elevated level of serum alkaline phosphatase (ALP) and microvascular invasion were all associated with a shorter OS, whereas an elevated serum alanine aminotransferase (ALT) level was correlated with inferior RFS.

Variables showing statistical significance by univariate analysis were included in the multivariate Cox proportional hazard analysis (Tables 2 and 3). As tumor size, portal vein thrombus and serum albumin level were all associated with BCLC stage, we did not enter these variables into further multivariate models so as to avoid potential bias. The results revealed that a high preoperative LMR level was an independent predictor of favorable prognostic measures, including OS (HR = 0.398; 95%CI: 0.219–0.725, *P* = 0.003) and RFS (HR = 0.584; 95%CI: 0.398–0.859; *P* = 0.006).Among the remaining factors studied, poor histological differentiation and an advanced BCLC stage were identified as independent indicators for inferior RFS and OS. In addition, cirrhotic liver parenchyma, an elevated serum ALP level and microvascular invasion were independent factors for OS.

***Comparisons of OS and RFS rates according to LMR level***

Kaplan–Meier curve analysis revealed that a low LMR level was significantly associated with decreased OS and DFS. The 5-year OS and RFS rates were 61.9% and 27.8%, respectively, for patients with a preoperative LMR ≤ 3.23 and were statistically lower than those for patients with a LMR > 3.23 (83.2% and 47.6%, respectively; *P* < 0.001 and *P* = 0.009, respectively; Figure 2A and 2B). Subgroup analysis was performed according to underlying cirrhosis status (cirrhosis, *n =* 161; non-cirrhosis, *n =* 49). In cirrhotic patients with HCC, a low preoperative LMR level was associated with inferior OS and RFS (*P* = 0.003 and *P* = 0.022, respectively; Figure 3A and 3B). However, there were no differences between low and high LMR levels for OS and RFS in non-cirrhotic patients (*P* = 0.443 and *P* = 0.492, respectively).

**DISCUSSION**

Accumulating studies have suggested that the infiltrating inflammatory microenvironment may represent an important determinant for the clinical outcome of HCC[7-12]. The imbalance of inflammatory immune cells, such as TAMs and TILs, in the tumor microenvironment, has been proven to be important regulator of progression in HCC[11-16]. Systemic inflammatory response can be routinely determined by traditional hematological markers, such as C-reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR), which are considered to be valuable prognostic factors in patients with HCC[27-30]. Peripheral blood LMR, as a novel inflammatory biomarker, has been recently investigated and confirmed to be a predictor of clinical outcomes in lymphoma[19,20], colon cancer[21], non-small cell lung cancer[23], nasopharyngeal carcinoma[22], breast cancer[24] andgastric cancer[25].

To the best of our knowledge, this is the first study to investigate the preoperative LMR as a prognostic marker in HCC patients initially treated with curative hepatectomy. Only HBV-related HCC was included to avoid potential confounding factors from different etiologies. An objective and reliable cutoff point for LMR was generated by employing ROC curve analysis. Univariate analysis revealed that patients with a LMR > 3.23 had significantly better OS and RFS than those with a LMR ≤ 3.23. On multivariate analysis, LMR remained an independent prognostic marker for OS and RFS throughout thecohort. These results were consistent with previous findings on other types of tumors, in which a low pretreatment level of LMR was reported as an independent unfavorable prognostic factor[19-25]. However,the cutoff values were cancer-specific in the above studies, possibly reflecting the biologic differences among these studied malignancies.

The association between decreased LMR and poor oncologic outcome is complex and remains to be elucidated. There are several possible reasons accounting for this positive correlation. Firstly, lymphocytes are the basic components of host antitumor immunity, which are important in the destruction of residual cancer cells and related micrometastases[20-22]. They infiltrate into tumor microenvironment and manifest as TILs, both the quantity and the phenotype of which may influence the effectiveness of antitumor immune reaction[8-10]. Unitt *et al*[8]found that reduced lymphocyte infiltration and a low CD4+:CD8+ T cell ratio were both significant independent predictors of HCC recurrence following liver transplantation. Two additional studies demonstrated that low intratumoral cytotoxic CD8+ T and high intratumoral regulatory T cells were associated with a poorer prognosis in HCC patients after resection[9,10]. In general, peripheral blood lymphocyte count serves as a simple surrogate marker of the host immune status. In our study, an association between a low level of ALC and adverse OS was identified by univariate analysis. We also revealed that patients with a decreased LMR have relative lymphocytopenia, which might be responsible for an incompetent immune response against tumor[20-22].

Secondly, myeloid-lineage cells, including monocytes and their progeny, are known to have immune suppressive activity[31]. They can also promote tumor angiogenesis, tumor-cell invasion and metastasis[21,31]. Circulating monocytes are recruited to the tumor stroma and differentiate into TAMs. As a major component of tumor microenvironment in HCC, TAMs can interact with cancer cells to enhance tumor progression by producing various cytokines and chemokines[11-15]. Poor clinical outcomes associated with high infiltrations of TAMs have been indicated by Zhu *et al*[15]and Kong *et al*[16].Peripheral blood monocytes may reflect the formation or existence of TAMs[23]. The pro-tumorigenic effect of monocytes on HCC has been associated with poor prognosis, as demonstrated by Sasaki *et al*[17] and Shen *et al*[18] and validated in the current study, which showed that monocytosis was associated with poor OS in patients with HCC after resection.

These data indicate that LMR might act as the surrogate marker which reflects the interaction between host immunity (*i.e*., ALC) and tumor microenvironment (*i.e*., AMC). The presence of preoperative lymphopenia and monocytosis both served as predictors for inferior OS in our study. However, as the combination of ALC and AMC, LMR provided a better prognostic value. A decreased LMR reflects an inflammatory status that favors tumor progression and impairs host immune surveillance, both of which are associated with poor oncologic outcome. Pretreatment LMR level was also inversely correlated with the presence of liver cirrhosis, and the poor outcome predicted by low LMR level was shown only in cirrhotic patients, not in non-cirrhotic ones. These results indicate that the association between cirrhosis and LMR may be an important mechanism for HCC progression.

LMR is a simple and easily assessable clinical biomarker for prognostic stratification of HBV-associated HCC patients after hepatectomy. However, findings of the current study should be interpreted within its possible limitations. Firstly, formal investigations on the specific components of tumor microenvironment in this population were not performed. Secondly, due to the retrospective design of the study, selection bias was inevitable, which might have influenced the survival analysis. Thirdly, as the study cohort was comprised of a small single-center sample, we were unable to divide the data set into a training set and a testing set for statistical validation.

In conclusion, our study is the first to demonstrate that preoperative LMR can serve as an independent prognostic factor for patients with HBV-associated HCC undergoing curative resection. As a simple and cost-effective biomarker, LMR could be used to identify HCC patients with a poorer survival, especially those with cirrhotic livers, which may guide postoperative treatment. Future biological studies should further correlate LMR with the tumor microenvironment. Prospective studies with larger cohorts are awaited to validate the clinical usages of LMR as a prognostic marker for HCC patients.

**ACKNOWLEDGMENTS**

The authors thank the surgeons and nurses in the Department of Liver Surgery, The Third Affiliated Hospital of Sun Yat-sen University for their help in treating the patients in this study.

**COMMENTS**

***Background***

Cumulative evidence has suggested that the inflammatory microenvironment may represent an important determinant for the clinical outcome of hepatocellular carcinoma (HCC). Peripheral blood lymphocyte-to-monocyte ratio (LMR), which is a novel inflammatory biomarker combining estimates of host immune homeostasis and tumor microenvironment, has been demonstrated to serve as a predictor of clinical outcomes in various types of malignancies. However, the prognostic value of LMR in patients with HCC remains unknown.

***Research frontiers***

The prognostic value of LMR has been widely investigated in hematological malignancies such as diffuse large B-cell lymphoma and Hodgkin's lymphoma. However, data regarding the prognostic value of LMR in patients with solid tumors are spare. Recent published studies have shown that preoperative high level of LMR was a favorable prognostic factor in patients with operable lung cancer and colon cancer. Prior to this study, there have been no reports regarding the prognostic value of LMR in patients with HCC until now.

***Innovations and breakthroughs***

To date, this is the first study to investigate the preoperative LMR as a prognostic biomarker in HCC patients after curative resection. To avoid any potential confounding factors from different etiologies, the authors included only hepatitis B virus-associated HCC patients. They also calculated the optimal LMR cutoff for survival prediction. The results identified that a low LMR level (≤ 3.23) was a significantly independent predictor of inferior survival in HCC patients who were initially treated with curative hepatectomy, suggesting that preoperative LMR represents a promising prognostic marker for HCC.

***Applications***

The study indicated that a low preoperative LMR level was an independent unfavorable prognostic factor for HCC patients who underwent curative hepatectomy. As a simple and cost-effective biomarker, LMR can be used to identifying HCC patients with a poorer survival, especially those with cirrhotic livers, which may guide postoperative treatment.

***Terminology***

The LMR was calculated by dividing the lymphocyte count by the monocyte count in peripheral blood.

***Peer-review***

This is an interesting study with sound methodology and statistical analyses, in which the authors investigated the prognostic value of preoperative LMR in HCC patients undergoing curative hepatectomy. The results suggest that a low preoperative LMR level was an independent unfavorable prognostic factor.

**References**

1 **Sherman M**. Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. *Semin Liver Dis* 2010; **30**: 3-16 [PMID: 20175029 DOI: 10.1055/s-0030-1247128]

2 **Bruix J**, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology* 2011; **53**: 1020-1022 [PMID: 21374666 DOI: 10.1002/hep.24199]

3 **Imamura H**, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T, Kawasaki S, Makuuchi M. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. *J Hepatol* 2003; **38**: 200-207 [PMID: 12547409 DOI: 10.1016/S0168-8278(02)00360-4]

4 **Gluer AM**, Cocco N, Laurence JM, Johnston ES, Hollands MJ, Pleass HC, Richardson AJ, Lam VW. Systematic review of actual 10-year survival following resection for hepatocellular carcinoma. *HPB (Oxford)* 2012; **14**: 285-290 [PMID: 22487065 DOI: 10.1111/j.1477-2574.2012.00446.x]

5 **Shah SA**, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, Langer B, Grant DR, Greig PD, Gallinger S. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. *Surgery* 2007; **141**: 330-339 [PMID: 17349844 DOI: 10.1016/j.surg.2006.06.028]

6 **Sumie S**, Kuromatsu R, Okuda K, Ando E, Takata A, Fukushima N, Watanabe Y, Kojiro M, Sata M. Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. *Ann Surg Oncol* 2008; **15**: 1375-1382 [PMID: 18324443 DOI: 10.1245/s10434-008-9846-9]

7 **Allavena P**, Sica A, Solinas G, Porta C, Mantovani A. The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. *Crit Rev Oncol Hematol* 2008; **66**: 1-9 [PMID: 17913510 DOI: 10.1016/j.critrevonc.2007.07.004]

8 **Unitt E**, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL, Morris LS, Coleman N, Alexander GJ. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. *J Hepatol* 2006; **45**: 246-253 [PMID: 16580084 DOI: 10.1016/j.jhep.2005.12.027]

9 **Gao Q**, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW, Tang ZY. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. *J Clin Oncol* 2007; **25**: 2586-2593 [PMID: 17577038 DOI: 10.1200/JCO.2006.09.4565]

10 **Chen KJ**, Zhou L, Xie HY, Ahmed TE, Feng XW, Zheng SS. Intratumoral regulatory T cells alone or in combination with cytotoxic T cells predict prognosis of hepatocellular carcinoma after resection. *Med Oncol* 2012; **29**: 1817-1826 [PMID: 21678026 DOI: 10.1007/s12032-011-0006-x]

11 **Peng SH**, Deng H, Yang JF, Xie PP, Li C, Li H, Feng DY. Significance and relationship between infiltrating inflammatory cell and tumor angiogenesis in hepatocellular carcinoma tissues. *World J Gastroenterol* 2005; **11**: 6521-6524 [PMID: 16425427]

12 **Wu K**, Kryczek I, Chen L, Zou W, Welling TH. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. *Cancer Res* 2009; **69**: 8067-8075 [PMID: 19826049 DOI: 10.1158/0008-5472.CAN-09-0901]

13 **Zhou J**, Ding T, Pan W, Zhu LY, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. *Int J Cancer* 2009; **125**: 1640-1648 [PMID: 19569243 DOI: 10.1002/ijc.24556]

14 **Mano Y**, Aishima S, Fujita N, Tanaka Y, Kubo Y, Motomura T, Taketomi A, Shirabe K, Maehara Y, Oda Y. Tumor-associated macrophage promotes tumor progression via STAT3 signaling in hepatocellular carcinoma. *Pathobiology* 2013; **80**: 146-154 [PMID: 23364389 DOI: 10.1159/000346196]

15 **Zhu XD**, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY, Sun HC. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. *J Clin Oncol* 2008; **26**: 2707-2716 [PMID: 18509183 DOI: 10.1200/JCO.2007.15.6521]

16 **Kong LQ**, Zhu XD, Xu HX, Zhang JB, Lu L, Wang WQ, Zhang QB, Wu WZ, Wang L, Fan J, Tang ZY, Sun HC. The clinical significance of the CD163+ and CD68+ macrophages in patients with hepatocellular carcinoma. *PLoS One* 2013; **8**: e59771 [PMID: 23555776 DOI: 10.1371/journal.pone.0059771]

17 **Sasaki A**, Iwashita Y, Shibata K, Matsumoto T, Ohta M, Kitano S. Prognostic value of preoperative peripheral blood monocyte count in patients with hepatocellular carcinoma. *Surgery* 2006; **139**: 755-764 [PMID: 16782430]

18 **Shen SL**, Fu SJ, Huang XQ, Chen B, Kuang M, Li SQ, Hua YP, Liang LJ, Peng BG. Elevated preoperative peripheral blood monocyte count predicts poor prognosis for hepatocellular carcinoma after curative resection. *BMC Cancer* 2014; **14**: 744 [PMID: 25280428 DOI: 10.1186/1471-2407-14-744]

19 **Porrata LF**, Ristow K, Colgan JP, Habermann TM, Witzig TE, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Nowakowski GS, Thompson C, Markovic SN. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma. *Haematologica* 2012; **97**: 262-269 [PMID: 21993683 DOI: 10.3324/haematol.2011.050138]

20 **Li ZM**, Huang JJ, Xia Y, Sun J, Huang Y, Wang Y, Zhu YJ, Li YJ, Zhao W, Wei WX, Lin TY, Huang HQ, Jiang WQ. Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP. *PLoS One* 2012; **7**: e41658 [PMID: 22911837 DOI: 10.1371/journal.pone.0041658]

21 **Stotz M**, Pichler M, Absenger G, Szkandera J, Arminger F, Schaberl-Moser R, Samonigg H, Stojakovic T, Gerger A. The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. *Br J Cancer* 2014; **110**: 435-440 [PMID: 24357796 DOI: 10.1038/bjc.2013.785]

22 **Li J**, Jiang R, Liu WS, Liu Q, Xu M, Feng QS, Chen LZ, Bei JX, Chen MY, Zeng YX. A large cohort study reveals the association of elevated peripheral blood lymphocyte-to-monocyte ratio with favorable prognosis in nasopharyngeal carcinoma. *PLoS One* 2013; **8**: e83069 [PMID: 24386144 DOI: 10.1371/journal.pone.0083069]

23 **Hu P**, Shen H, Wang G, Zhang P, Liu Q, Du J. Prognostic significance of systemic inflammation-based lymphocyte- monocyte ratio in patients with lung cancer: based on a large cohort study. *PLoS One* 2014; **9**: e108062 [PMID: 25275631 DOI: 10.1371/journal.pone.0108062]

24 **Ni XJ**, Zhang XL, Ou-Yang QW, Qian GW, Wang L, Chen S, Jiang YZ, Zuo WJ, Wu J, Hu X, Shao ZM. An elevated peripheral blood lymphocyte-to-monocyte ratio predicts favorable response and prognosis in locally advanced breast cancer following neoadjuvant chemotherapy. *PLoS One* 2014; **9**: e111886 [PMID: 25372468 DOI: 10.1371/journal.pone.0111886]

25 **Zhou X**, Du Y, Xu J, Huang Z, Qiu T, Wang X, Qian J, Zhu W, Liu P. The preoperative lymphocyte to monocyte ratio predicts clinical outcomes in patients with stage II/III gastric cancer. *Tumour Biol* 2014; **35**: 11659-11666 [PMID: 25139101 DOI: 10.1007/s13277-014-2504-x]

26 *Omata M*, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P,Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. *Hepatol Int* 2010; **4**: 439-474 [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7]

27 **Oh BS**, Jang JW, Kwon JH, You CR, Chung KW, Kay CS, Jung HS, Lee S. Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma. *BMC Cancer* 2013; **13**: 78 [PMID: 23409924 DOI: 10.1186/1471-2407-13-7]

28 **Mano Y**,Shirabe K, Yamashita Y, Harimoto N, Tsujita E, Takeishi K, Aishima S, Ikegami T, Yoshizumi T, Yamanaka T, Maehara Y. Preoperative neutrophil-to-lymphocyte ratio is a predictor of survival after hepatectomy for hepatocellular carcinoma: a retrospective analysis. *Ann Surg* 2013; **258**: 301-305 [PMID: 23774313 DOI: 10.1097/SLA.0b013e318297ad6b]


29 **Fu SJ**, Shen SL, Li SQ, Hua YP, Hu WJ, Liang LJ, Peng BG. Prognostic value of preoperative peripheral neutrophil-to-lymphocyte ratio in patients with HBV-associated hepatocellular carcinoma after radical hepatectomy. *Med Oncol* 2013; **30**: 721 [PMID: 24026659 DOI: 10.1007/s12032-013-0721-6]

30 **Templeton AJ**, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JJ, Tran B, Tannock IF, Amir E. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *J Natl Cancer Inst* 2014; **106**: dju124 [PMID: 24875653 DOI: 10.1093/jnci/dju124]

31 **Gabrilovich DI**, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol* 2009; **9**: 162-174 [PMID: 19197294 DOI: 10.1038/nri2506]


**P-Reviewer:** Montasser Iman F, Peng BG, Sturesson C **S-Editor:** Yu J

**L-Editor:** **E-Editor:**


****

**Figure 1 Receiver operating characteristics curve assessing the cutoff value of lymphocyte-to-monocyte ratio for survival analyses in patients with hepatitis B virus -associated hepatocellular carcinoma treated by curative hepatectomy.**

**A**


****

**B**


****

**Figure 2 Kaplan-Meier survival analysis of preoperative lymphocyte-to-monocyte ratio in patients with hepatocellular carcinoma undergoing curative resection.** A: Overall survival according to lymphocyte-to-monocyte ratio (LMR); B: Recurrence-free survival according to LMR.

**A**

.

**B**



**Figure 3 Kaplan-Meier survival analysis of preoperative lymphocyte-to-monocyte ratio in cirrhotic patients with hepatocellular carcinoma undergoing curative resection.** A: Overall survival according to lymphocyte-to-monocyte ratio (LMR); B: Recurrence-free survival according to LMR.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 1 Relationship between lymphocyte-to-monocyte ratio and clinicopathological characteristics** | | | | |
| **Variables** | **No. of patients** | **LMR** | | ***P* value** |
| **≤ 3.23 (*n =* 66)** | **> 3.23 (*n =* 144)** |
| Age (yr) |  |  |  |  |
| < 60 | 165 | 52 | 113 | 0.959 |
| ≥ 60 | 45 | 14 | 31 |  |
| Gender |  |  |  |  |
| Female | 25 | 6 | 19 | 0.394 |
| Male | 185 | 60 | 125 |  |
| Liver cirrhosis |  |  |  |  |
| Absent | 49 | 7 | 42 | **0.003** |
| Present | 161 | 59 | 102 |  |
| ALT (U/L) |  |  |  |  |
| ≤ 75 | 172 | 51 | 121 | 0.238 |
| > 75 | 38 | 15 | 23 |  |
| Total bilirubin (μmol/L) |  |  |  |  |
| ≤ 34 | 197 | 57 | 140 | 0.002 |
| > 34 | 13 | 9 | 4 |  |
| Albumin (g/L) |  |  |  |  |
| < 35 | 15 | 7 | 8 | 0.303 |
| ≥ 35 | 195 | 59 | 136 |  |
| ALP (U/L) |  |  |  |  |
| ≤ 100 | 171 | 51 | 120 | 0.294 |
| > 100 | 39 | 15 | 24 |  |
| AFP (ng/dL)  300 ng/dl |  |  |  |  |
| ≤ 400 | 124 | 38 | 86 | 0.769 |
| > 400 | 86 | 28 | 58 |  |
| Tumor size (cm)  5cm |  |  |  |  |
| ≤ 5 | 157 | 43 | 114 | 0.030 |
| > 5 | 53 | 23 | 30 |  |
| Tumor number |  |  |  |  |
| Single | 184 | 59 | 125 | 0.597 |
| Multiple | 26 | 7 | 19 |  |
| Portal vein thrombus |  |  |  |  |
| Absent | 196 | 61 | 135 | 0.952 |
| Present | 14 | 5 | 9 |  |
| Microvascular invasion |  |  |  |  |
| Absent | 170 | 55 | 115 | 0.552 |
| Present | 40 | 11 | 29 |  |
| Histological differentiation |  |  |  |  |
| Poor | 22 | 8 | 14 | 0.598 |
| Well and Moderate | 188 | 58 | 130 |  |
| ALC (× 109/L) |  |  |  |  |
| ≤ 1.66 | 117 | 50 | 67 | < 0.001 |
| > 1.66 | 93 | 16 | 77 |  |
| AMC (× 109/L) |  |  |  |  |
| ≤ 0.29 | 57 | 3 | 54 | < 0.001 |
| > 0.29 | 153 | 63 | 90 |  |

AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; ALC: Absolute lymphocyte count; ALP: Alkaline phosphatase; AMC: Absolute monocyte count; LMR: Lymphocyte-to-monocyte ratio.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Table 2 Cox proportional hazards model of prognostic factors for overall survival in 210 patients with hepatocellular carcinoma after curative hepatectomy** | | | | |
| **Variables** | **Univariate analysis** | | **Multivariate analysis** | | |
| **HR ( 95%CI )** | ***P value*** | **HR ( 95%CI )** | ***P value*** | |
| Age (yr), ≥ 60 *vs* < 60 | 0.766 (0.410–1.433) | 0.404 |  |  | |
| Gender, male *vs* female | 0.829 (0.296–2.321) | 0.721 |  |  | |
| Liver cirrhosis, yes *vs* no | 7.641 (1.853–31.509) | 0.005 | 7.084 (1.694–29.614) | 0.007 | |
| ALT (U/L), > 75 *vs* ≤ 75 | 1.513 (0.771–2.970) | 0.229 |  |  | |
| Total bilirubin (μmol/L), > 34 *vs* ≤ 34 | 2.085 (0.822–5.288) | 0.122 |  |  | |
| Albumin (g/L), ≥ 35 *vs* < 35 | 0.242 (0.112–0.522) | < 0.001 |  |  | |
| ALP (U/L), > 100 *vs* ≤ 100 | 2.116 (1.148–3.899) | 0.016 | 2.137 (1.153–3.964) | 0.016 | |
| AFP (ng/dL), > 400 *vs* ≤ 400  300 ng/dl | 0.956 (0.535–1.705) | 0.878 |  |  | |
| Tumor size (cm), > 5 *vs* ≤ 5  5cm | 2.154 (1.204–3.853) | 0.010 |  |  | |
| Tumor number, multiple *vs* single | 1.048 (0.444–2.477) | 0.915 |  |  | |
| Portal vein thrombus: yes *vs* no | 3.348 (1.492–7.512) | 0.003 |  |  | |
| Microvascular invasion: yes *vs* no | 2.121 (1.151–3.911) | 0.016 | 2.307 (1.217– 4.370) | 0.010 | |
| Histological differentiation, poor *vs* well and moderate | 2.888 (1.467–5.684) | 0.002 | 2.375 (1.195–4.721) | 0.014 | |
| BCLC stage, B + C *vs* 0 + A | 2.110 (1.197–3.720) | 0.010 | 2.155 (1.213–3.831) | 0.009 | |
| Preoperative LMR, > 3.23 *vs* ≤ 3.23 | 0.352 (0.199–0.623) | < 0.001 | 0.398 (0.219–0.725) | 0.003 | |

AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; BCLC: Barcelona Clinic Liver Cancer; LMR: Lymphocyte-to-monocyte ratio.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Table 3 Cox proportional hazards model of prognostic factors for recurrence-free survival in 210 patients with hepatocellular carcinoma after curative hepatectomy** | | | | | |
| **Variables** | **Univariate analysis** | | **Multivariate analysis** | |
| **HR (95%CI)** | ***P* value** | **HR (95%CI)** | ***P* value** |
| Age(yr), ≥ 60 *vs* < 60 | 1.319 (0.859 – 2.027) | 0.206 |  |  |
| Gender, male *vs* female | 0.855 (0.458 – 1.594) | 0.621 |  |  |
| Liver cirrhosis: yes *vs* no | 1.316 (0.831 – 2.086) | 0.242 |  |  |
| ALT (U/L), > 75 *vs* ≤ 75 | 1.709 (1.096 – 2.665) | 0.018 | 1.510 (0.960 – 2.375) | 0.074 |
| Total bilirubin (μmol/L), > 34 *vs* ≤ 34 | 1.471 (0.715 – 3.023) | 0.294 |  |  |
| Albumin (g/L), ≥ 35 *vs* < 35 | 0.279 (0.160 – 0.485) | < 0.001 |  |  |
| ALP (U/L), > 100 *vs* ≤ 100 | 1.506 (0.964 – 2.354) | 0.072 |  |  |
| AFP (ng/dL), > 400 *vs* ≤ 400  300 ng/dl | 0.934 (0.636 – 1.373) | 0.730 |  |  |
| Tumor size (cm), > 5 *vs* ≤ 5  5cm | 2.020 (1.354 – 3.012) | 0.001 |  |  |
| Tumor number, multiple *vs* single | 1.599 (0.953 – 2.684) | 0.075 |  |  |
| Portal vein thrombus, yes *vs* no | 2.282 (1.150 – 4.529) | 0.018 |  |  |
| Microvascular invasion, yes *vs* no | 1.185 (0.742 – 1.892) | 0.478 |  |  |
| Histological differentiation, poor *vs* well and moderate | 2.628 (1.561 – 4.425) | < 0.001 | 2.610 (1.542– 4.416) | < 0.001 |
| BCLC stage, B + C *vs* 0 + A | 1.724 (1.180 – 2.520) | 0.005 | 1.645 (1.124 – 2.409) | 0.010 |
| Preoperative LMR, > 3.23 *vs* ≤ 3.23 | 0.601 (0.410 – 0.883) | 0.009 | 0.584 (0.398– 0.859) | 0.006 |

AFP: Alpha-fetoprotein; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; BCLC: Barcelona Clinic Liver Cancer; LMR: Lymphocyte-to-monocyte ratio.